Kevin Eggan

QurAlis Corp. engages in discovering and developing new therapies for amyotrophic lateral sclerosis and other neurological diseases. It offers therapeutic programs and targets, and biomarkers. The company was founded by Clifford Woolf, Kevin Eggan, Jonathan J. Fleming, and Kasper Roet and is headquartered in North Cambridge, MA.

The Broad Institute, Inc. engages in the provision of research and development in biomedicals to cure infectious disease. Its scientific areas include chemical biology and therapeutics, genome regulation, cellular circuity and epigenomics, medical and population genetics, and metabolism. The company was founded by Eric S. Lander, Eli Broad and Edythe Broad in 2003 and is headquartered in Cambridge, MA.

Enclear Therapies, Inc. develops and manufactures novel device-based therapies to treat patients. The firm device is developed to treat and halt the progression of neurodegenerative diseases by removing toxic proteins known to drive pathology. The company was founded by Anthony R. DePasqua, Jonathan J. Fleming, Kasper Roet, William B. Gormley and Kevin Eggan and is headquartered in Newburyport, MA.

Harvard University engages in the provision of teaching and research. It has twelve degree-granting Schools in addition to the Radcliffe Institute for Advanced Study, offering a global education. The university was founded in 1636 and is headquartered in Cambridge, MA.

Q-State Biosciences, Inc. operates as Biotechnology Company. It offers cardiology, neurology, toxicity screening, drug discovery, drug efficacy screening, pathology modeling, optogenetic, electrophysiology, voltage and calcium signal. The company was founded by Adam E. Cohen, Kevin Eggan, David Margulies and Joel Kralj and is headquartered in Cambridge, MA.